Impact of anaemia on long-term outcomes in patients treated with first- and second-generation drug-eluting stents; Katowice-Zabrze Registry

2015 ◽  
pp. 561-569 ◽  
Author(s):  
Wojciech Wańha ◽  
Damian Kawecki ◽  
Tomasz Roleder ◽  
Aleksandra Pluta ◽  
Kamil Marcinkiewicz ◽  
...  
Keyword(s):  
Second Generation ◽  
Drug Eluting Stents ◽  
Long Term Outcomes ◽  
Drug Eluting ◽  
First And Second Generation

P1966Impact of coronary artery calcification on long-term outcomes after implantation of first and second-generation drug-eluting stents: a patient-level analysis of 18 randomized trials

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
P Guedeney ◽  
B Claessen ◽  
R Mehran ◽  
G Mintz ◽  
M Liu ◽  
...  
Keyword(s):  
Randomized Trials ◽  
Second Generation ◽  
Composite Endpoint ◽  
Target Lesion ◽  
Drug Eluting Stents ◽  
Patient Level ◽  
Drug Eluting ◽  
Long Term Impact ◽  
First And Second Generation

Abstract Background Available data on the long-term impact of coronary artery calcification (CAC) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) are limited. Purpose We evaluated the long-term impact of CAC on outcomes after PCI and the respective performance of first- and second-generation DES. Methods We pooled patient-level data from 18 randomized trials evaluating DES categorized according to the presence of angiographic core lab-confirmed moderate or severe CAC in any target lesion. Outcome measures of interest were the patient-oriented composite endpoint (POCE; death, myocardial infarction [MI], or any revascularization), the device-oriented composite endpoint of target lesion failure (TLF; cardiac death, target vessel MI or ischemia-driven target lesion revascularization), and definite or probable stent thrombosis (ST). Multivariable Cox proportional regression with study as a random effect was used to assess 5-year outcomes. Results A total of 19,833 patients were included. Moderate or severe CAC was present in 6211 (31.3%) patients and associated with increased 5-year risk of the POCE (adjHR 1.12, 95% CI 1.05–1.20, p<0.001), TLF (adjHR 1.21, 95% CI 1.09–1.35, p<0.001), and a trend for greater ST (adjHR 1.24, 95% CI 0.99–1.54, p=0.06). In patients with CAC, second-generation DES were associated with a reduction in the 5-year risk of TLF and ST, and a trend for reduced POCE compared with first-generation DES (Table). Conclusion In this large-scale study, target lesion moderate or severe CAC was associated with adverse patient- and device-related outcomes at 5 years, risks that were reduced but not eliminated with second-generation DES. Acknowledgement/Funding This investigator-sponsored study was funded by Abbott Vascular.

Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions

2015 ◽  
Vol 87 (1) ◽  
pp. 34-40 ◽  
Author(s):  
Nagendra R. Pokala ◽  
Rohan V. Menon ◽  
Siddharth M. Patel ◽  
George Christopoulos ◽  
Georgios E. Christakopoulos ◽  
...  
Keyword(s):  
Saphenous Vein ◽  
Vein Graft ◽  
Second Generation ◽  
Saphenous Vein Graft ◽  
Drug Eluting Stents ◽  
Long Term Outcomes ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document